Beam Therapeutics Adds Harvard Professor to Board
Ticker: BEAM · Form: 8-K · Filed: Jul 15, 2024
Sentiment: neutral
Topics: board-appointment, personnel
TL;DR
Beam Therapeutics adds Harvard immunology expert Dr. Sarah Fortune to its board.
AI Summary
Beam Therapeutics Inc. announced on July 11, 2024, the election of Dr. Sarah E. Fortune to its Board of Directors. Dr. Fortune is a distinguished professor and chair of the Department of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health. Her expertise is expected to bolster the company's strategic direction in gene editing therapies.
Why It Matters
The appointment of a prominent academic like Dr. Fortune to the board can signal enhanced scientific rigor and strategic insight for Beam Therapeutics' gene editing platform.
Risk Assessment
Risk Level: low — The filing is an 8-K reporting a routine board appointment, not a material financial event.
Key Players & Entities
- Beam Therapeutics Inc. (company) — Registrant
- Dr. Sarah E. Fortune (person) — Newly elected Director
- Harvard T.H. Chan School of Public Health (company) — Dr. Fortune's affiliation
- July 11, 2024 (date) — Date of earliest event reported
FAQ
Who is Dr. Sarah E. Fortune and what is her role at Beam Therapeutics?
Dr. Sarah E. Fortune is a professor and chair of the Department of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health, and she has been elected to the Board of Directors of Beam Therapeutics Inc.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 11, 2024.
What is the primary business of Beam Therapeutics Inc. according to the filing?
Beam Therapeutics Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
What is the principal executive office address for Beam Therapeutics Inc.?
The principal executive office address is 238 Main Street, Cambridge, Massachusetts, 02142.
What type of SEC filing is this and what items are being reported?
This is a Form 8-K (Current Report) reporting on the departure of directors or certain officers; election of directors; appointment of certain officers; and compensatory arrangements of certain officers, as well as financial statements and exhibits.
Filing Stats: 563 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-07-15 07:01:29
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share BEAM Nasdaq Global Select
Filing Documents
- d723042d8k.htm (8-K) — 26KB
- d723042dex991.htm (EX-99.1) — 8KB
- g723042logo.jpg (GRAPHIC) — 7KB
- 0001193125-24-178824.txt ( ) — 163KB
- beam-20240711.xsd (EX-101.SCH) — 3KB
- beam-20240711_lab.xml (EX-101.LAB) — 17KB
- beam-20240711_pre.xml (EX-101.PRE) — 11KB
- d723042d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No Description 99.1 Press Release Issued by Beam Therapeutics Inc. on July 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 15, 2024 Beam Therapeutics Inc. By: /s/ John Evans Name: John Evans Title: Chief Executive Officer